COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015): an ongoing global Parkinson's disease project about disease progression with more than 1000 subjects included. Results from the baseline evaluation
Corresponding Author
D. Santos García
CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain
Correspondence: D. Santos García, Department of Neurology, Hospital Universitario de A Coruña HUAC), Complejo Hospitalario Universitario de A Coruña (CHUAC), c/ As Xubias 84, 15006, A Coruña Spain (tel.: 981 334000; fax: 981 334015; e-mail: [email protected]).Search for more papers by this authorS. Jesús
Hospital Universitario Virgen del Rocío, Sevilla, Spain
Search for more papers by this authorM. Aguilar
Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain
Search for more papers by this authorJ. García Caldentey
Centro Neurológico Oms 42, Palma de Mallorca, Spain
Search for more papers by this authorN. Caballol
Consorci Sanitari Integral, Hospital Moisés Broggi, Sant Joan Despí, Barcelona, Spain
Search for more papers by this authorI. Legarda
Hospital Universitario Son Espases, Palma de Mallorca, Spain
Search for more papers by this authorJ. Hernández Vara
Hospital Universitario Vall d'Hebron, Barcelona, Spain
Search for more papers by this authorI. Cabo
Complejo Hospitalario Universitario de Pontevedra (CHOP), Pontevedra, Spain
Search for more papers by this authorL. López Manzanares
Hospital Universitario La Princesa, Madrid, Spain
Search for more papers by this authorI. González Aramburu
Hospital Universitario Marqués de Valdecilla, Santander, Spain
Search for more papers by this authorM. A. Ávila Rivera
Consorci Sanitari Integral, Hospital General de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain
Search for more papers by this authorM. J. Catalán
Hospital Universitario Clínico San Carlos, Madrid, Spain
Search for more papers by this authorL. López Díaz
Complejo Hospitalario Universitario de Orense (CHUO), Orense, Spain
Search for more papers by this authorJ. M. García Moreno
Hospital Universitario Virgen Macarena, Sevilla, Spain
Search for more papers by this authorB. Solano Vila
Institut d'Assistència Sanitària (IAS) – Institut Català de la Salut, Girona, Spain
Search for more papers by this authorM. Álvarez Sauco
Hospital General Universitario de Elche, Elche, Spain
Search for more papers by this authorS. Escalante
Hospital de Tortosa Verge de la Cinta (HTVC), Tortosa, Tarragona, Spain
Search for more papers by this authorE. Cubo
Complejo Asistencial Universitario de Burgos, Burgos, Spain
Search for more papers by this authorF. Carrillo Padilla
Hospital Universitario de Canarias, San Cristóbal de la Laguna, Santa Cruz de Tenerife, Spain
Search for more papers by this authorJ. C. Martínez Castrillo
Hospital Universitario Ramón y Cajal, Madrid, Spain
Search for more papers by this authorP. Sánchez Alonso
Hospital Universitario Puerta de Hierro, Madrid, Spain
Search for more papers by this authorM. G. Alonso Losada
Hospital Álvaro Cunqueiro, Complejo Hospitalario Universitario de Vigo (CHUVI), Vigo, Spain
Search for more papers by this authorN. López Ariztegui
Complejo Hospitalario de Toledo, Toledo, Spain
Search for more papers by this authorM. Menéndez González
Hospital Universitario Central de Asturias, Oviedo, Spain
Search for more papers by this authorM. Seijo
Complejo Hospitalario Universitario de Pontevedra (CHOP), Pontevedra, Spain
Search for more papers by this authorJ. Rúiz Martínez
Hospital Universitario Donostia, San Sebastián, Spain
Search for more papers by this authorO. de Fábregues-Boixar
Hospital Universitario Vall d'Hebron, Barcelona, Spain
Search for more papers by this authorJ. González Ardura
Hospital Universitario Lucus Augusti (HULA), Lugo, Spain
Search for more papers by this authorP. Martinez-Martin
Centro Nacional de Epidemiología y CIBERNED, Instituto de Salud Carlos III, Madrid, Spain
Search for more papers by this authoron behalf of the COPPADIS Study Group
†COPPADIS Study Group members are listed in the Acknowledgements.Search for more papers by this authorCorresponding Author
D. Santos García
CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain
Correspondence: D. Santos García, Department of Neurology, Hospital Universitario de A Coruña HUAC), Complejo Hospitalario Universitario de A Coruña (CHUAC), c/ As Xubias 84, 15006, A Coruña Spain (tel.: 981 334000; fax: 981 334015; e-mail: [email protected]).Search for more papers by this authorS. Jesús
Hospital Universitario Virgen del Rocío, Sevilla, Spain
Search for more papers by this authorM. Aguilar
Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain
Search for more papers by this authorJ. García Caldentey
Centro Neurológico Oms 42, Palma de Mallorca, Spain
Search for more papers by this authorN. Caballol
Consorci Sanitari Integral, Hospital Moisés Broggi, Sant Joan Despí, Barcelona, Spain
Search for more papers by this authorI. Legarda
Hospital Universitario Son Espases, Palma de Mallorca, Spain
Search for more papers by this authorJ. Hernández Vara
Hospital Universitario Vall d'Hebron, Barcelona, Spain
Search for more papers by this authorI. Cabo
Complejo Hospitalario Universitario de Pontevedra (CHOP), Pontevedra, Spain
Search for more papers by this authorL. López Manzanares
Hospital Universitario La Princesa, Madrid, Spain
Search for more papers by this authorI. González Aramburu
Hospital Universitario Marqués de Valdecilla, Santander, Spain
Search for more papers by this authorM. A. Ávila Rivera
Consorci Sanitari Integral, Hospital General de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain
Search for more papers by this authorM. J. Catalán
Hospital Universitario Clínico San Carlos, Madrid, Spain
Search for more papers by this authorL. López Díaz
Complejo Hospitalario Universitario de Orense (CHUO), Orense, Spain
Search for more papers by this authorJ. M. García Moreno
Hospital Universitario Virgen Macarena, Sevilla, Spain
Search for more papers by this authorB. Solano Vila
Institut d'Assistència Sanitària (IAS) – Institut Català de la Salut, Girona, Spain
Search for more papers by this authorM. Álvarez Sauco
Hospital General Universitario de Elche, Elche, Spain
Search for more papers by this authorS. Escalante
Hospital de Tortosa Verge de la Cinta (HTVC), Tortosa, Tarragona, Spain
Search for more papers by this authorE. Cubo
Complejo Asistencial Universitario de Burgos, Burgos, Spain
Search for more papers by this authorF. Carrillo Padilla
Hospital Universitario de Canarias, San Cristóbal de la Laguna, Santa Cruz de Tenerife, Spain
Search for more papers by this authorJ. C. Martínez Castrillo
Hospital Universitario Ramón y Cajal, Madrid, Spain
Search for more papers by this authorP. Sánchez Alonso
Hospital Universitario Puerta de Hierro, Madrid, Spain
Search for more papers by this authorM. G. Alonso Losada
Hospital Álvaro Cunqueiro, Complejo Hospitalario Universitario de Vigo (CHUVI), Vigo, Spain
Search for more papers by this authorN. López Ariztegui
Complejo Hospitalario de Toledo, Toledo, Spain
Search for more papers by this authorM. Menéndez González
Hospital Universitario Central de Asturias, Oviedo, Spain
Search for more papers by this authorM. Seijo
Complejo Hospitalario Universitario de Pontevedra (CHOP), Pontevedra, Spain
Search for more papers by this authorJ. Rúiz Martínez
Hospital Universitario Donostia, San Sebastián, Spain
Search for more papers by this authorO. de Fábregues-Boixar
Hospital Universitario Vall d'Hebron, Barcelona, Spain
Search for more papers by this authorJ. González Ardura
Hospital Universitario Lucus Augusti (HULA), Lugo, Spain
Search for more papers by this authorP. Martinez-Martin
Centro Nacional de Epidemiología y CIBERNED, Instituto de Salud Carlos III, Madrid, Spain
Search for more papers by this authoron behalf of the COPPADIS Study Group
†COPPADIS Study Group members are listed in the Acknowledgements.Search for more papers by this authorAbstract
Background and purpose
In Parkinson's disease (PD), the course of the disorder is highly variable between patients. Well-designed, prospective studies for identifying PD progression biomarkers are necessary. Our aim was to show the results of baseline evaluations of an ongoing global PD project, COPPADIS-2015 (Cohort of Patients with PArkinson's DIsease in Spain, 2015).
Methods
This was an observational, descriptive, nationwide study (Spain). The recruitment period ended in October 2017. Baseline evaluation included more than 15 validated scales and complementary studies in a subgroup of participants.
Results
In total, 1174 subjects from 35 centres were considered valid for baseline analysis: 694 patients (62.6 ± 8.9 years old, 60.3% males), 273 caregivers (58.5 ± 11.9 years old, 31.8% males) and 207 controls (61 ± 8.3 years old, 49.5% males). The mean disease duration was 5.5 ± 4.4 years. Hoehn and Yahr stage was 1 or 2 in 90.7% of the patients whilst 33.9% and 18.1% of them presented motor fluctuations and dyskinesias, respectively. The mean Non-Motor Symptoms Scale total score was 45.4 ± 38.1, and 30.4% of the patients presented cognitive impairment, 16.1% major depression, 12.7% impulse control disorder, 7.2% compulsive behaviour, 57.2% pain and 13.2% falls. Compared to the control group, PD patients presented a significantly higher burden of non-motor symptoms and a worse quality of life. More than 300 subjects conducted complementary studies (serum biomarkers, genetic and neuroimaging).
Conclusions
Parkinson's disease is a complex disorder and different non-motor symptoms are frequently present and are more prevalent than in controls. In real clinical practice it is important to ask for them.
Supporting Information
| Filename | Description |
|---|---|
| ene14008-sup-0001-FigS1.pdfPDF document, 653.4 KB | Figure S1. Recruitment period was from January 2016 to October 2017 (baseline assessment of each participating subject). 1A, patient inclusion process and motor assessment by the principal investigator (neurologist who is an expert in movement disorders and Parkinson's disease); 2A, non-motor assessment by the principal investigator, specialized nurse, psychologist or fellow with adequate training; 2B, caregiver assessment; 2C, control assessment. *Only patients with motor fluctuations (UPDRS-IV) were assessed during the OFF medication (first thing in the morning without taking medication in the previous 12 h) and during the ON medication state. |
| ene14008-sup-0002-Supinfo.docxWord document, 35.9 KB | Appendix S1. COPPADIS Study Group |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1Kalia LV, Lang AE. Parkinson's disease. Lancet 2015; 386: 896–912.
- 2Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson's disease. Nat Rev Neurosci 2017; 18: 435–450.
- 3Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR; NMSS Validation Group. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 2011; 26: 399–406.
- 4Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC. How to identify tremor dominant and postural instability/gait difficulty groups with the Movement Disorder Society Unified Parkinson's Disease Rating Scale: comparison with the Unified Parkinson's Disease Rating Scale. Mov Disord 2013; 28: 668–670.
- 5Sauerbier A, Jenner P, Todorova A, Chaudhuri KR. Non motor subtypes and Parkinson's disease. Parkinsonism Relat Disord 2016; 22(Suppl. 1): S41–S46.
- 6Titova N, Padmakumar C, Lewis SJG, Chaudhuri KR. Parkinson's: a syndrome rather than a disease? J Neural Transm (Vienna) 2017; 124: 907–914.
- 7Santos-García D, Mir P, Cubo E, et al. COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global–clinical evaluations, serum biomarkers, genetic studies and neuroimaging–prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression. BMC Neurol 2016; 16: 26.
- 8Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009; 24: 1641–1649.
- 9Martinez-Martin P, Rodriguez-Blazquez C, Abe K, et al. International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease. Neurology 2009; 73: 1584–1591.
- 10Hinnell C, Hurt CS, Landau S, Brown RG, Samuel M. Nonmotor versus motor symptoms: how much do they matter to health status in Parkinson's disease? Mov Disord 2012; 27: 236–241.
- 11Duncan GW, Khoo TK, Yarnall AJ, et al. Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms. Mov Disord 2014; 29: 195–202.
- 12Zhang TM, Yu SY, Guo P, et al. Nonmotor symptoms in patients with Parkinson disease: a cross-sectional observational study. Medicine (Baltimore) 2016; 95: e5400.
- 13Sauerbier A, Jitkritsadakul O, Titova N, et al. Non-motor symptoms assessed by Non-Motor Symptoms Questionnaire and Non-Motor Symptoms Scale in Parkinson's disease in selected Asian populations. Neuroepidemiology 2017; 49: 1–17.
- 14Simuni T, Caspell-Garcia C, Coffey CS, et al. Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort. J Neurol Neurosurg Psychiatry 2018; 89: 78–88.
- 15Khoo TK, Yarnall AJ, Duncan GW, et al. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology 2013; 80: 276–281.
- 16Pont-Sunyer C, Hotter A, Gaig C, et al. The onset of nonmotor symptoms in Parkinson's disease (the ONSET PD study). Mov Disord 2015; 30: 229–237.
- 17Krishnan S, Sarma G, Sarma S, Kishore A. Do nonmotor symptoms in Parkinson's disease differ from normal aging? Mov Disord 2011; 26: 2110–2113.
- 18Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011; 26(Suppl. 3): S42–S80.
- 19Muzerengi S, Contrafatto D, Chaudhuri KR. Non-motor symptoms in Parkinson's disease: an underdiagnosed problem. Parkinsonism Relat Disord 2007; 13 (Suppl. 3): S450–S456.
- 20Vela L, Martínez Castrillo JC, García Ruiz P, et al. The high prevalence of impulse control behaviors in patients with early-onset Parkinson's disease: a cross-sectional multicenter study. J Neurol Sci 2016; 368: 150–154.
- 21Silverdale MA, Kobylecki C, Kass-Iliyya L, et al. A detailed clinical study of pain in 1957 participants with early/moderate Parkinson's disease. Parkinsonism Relat Disord 2018; 56: 27–32.
- 22Goodarzi Z, Mrklas KJ, Roberts DJ, Jette N, Pringsheim T, Holroyd-Leduc J. Detecting depression in Parkinson disease: a systematic review and meta-analysis. Neurology 2016; 87: 426–437.
- 23Stocchi F, Antonini A, Barone P, et al. Early detection of wearing off in Parkinson disease: the DEEP study. Parkinsonism Relat Disord 2014; 20: 204–211.
- 24Santos-García D, de la Fuente-Fernández R. Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson's disease. J Neurol Sci 2013; 332: 136–140.
- 25Martínez-Martín P, Benito-León J, Alonso F, et al. Quality of life of caregivers in Parkinson's disease. Qual Life Res 2005; 14: 463–472.
- 26Oguh O, Kwasny M, Carter J, Stell B, Simuni T. Caregiver strain in Parkinson's disease: National Parkinson Foundation Quality Initiative Study. Parkinsonism Relat Disord 2013; 19: 975–979.
- 27Santos García D, Suárez Castro E, Expósito I, et al. Comorbid conditions associated with Parkinson's disease: a longitudinal and comparative study with Alzheimer disease and control subjects. J Neurol Sci 2017; 373: 210–215.
- 28Marek K, Jennings D, Tamagnan G, Seibyl J. Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression. Ann Neurol 2008; 64(Suppl. 2): S111–S121.
- 29Katunina E, Titova N. The epidemiology of nonmotor symptoms in Parkinson's disease (cohort and other studies). Int Rev Neurobiol 2017; 133: 91–110.
- 30Heinzel S, Lerche S, Maetzler W, Berg D. Global, yet incomplete overview of cohort studies in Parkinson's disease. J Parkinsons Dis 2017; 7: 423–432.
- 31Nombela C, Rowe JB, Winder-Rhodes SE, et al. Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study. Brain 2014; 137: 2743–2758.
- 32Burciu RG, Ofori E, Archer DB, et al. Progression marker of Parkinson's disease: a 4-year multi-site imaging study. Brain 2017; 140: 2183–2192.
- 33Kalbe E, Rehberg SP, Heber I, et al. Subtypes of mild cognitive impairment in patients with Parkinson's disease: evidence from the LANDSCAPE study. J Neurol Neurosurg Psychiatry 2016; 87: 1099–1105.
- 34Weintraub D, Mamikonyan E, Papay K, Shea JA, Xie SX, Siderowf A. Questionnaire for impulsive-compulsive disorders in Parkinson's disease-rating scale. Mov Disord 2012; 27: 242–247.
